Neurological complications of infliximab

Journal of Rheumatology

Volumn 33, Issue 5, 2006, Pages 1018-1020

  Jarand, Julie ^a   Zochodne, Douglas W ^b   Martin, Liam O ^a   Voll, Christopher ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Infliximab; Paresthesia; Polyneuropathy; Rheumatoid arthritis

Indexed keywords

CORTICOSTEROID; GABAPENTIN; INFLIXIMAB; LEFLUNOMIDE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; DEMYELINATING DISEASE; DEMYELINATION; DIPLOPIA; DRUG BINDING; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MUSCLE WEAKNESS; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; OUTCOMES RESEARCH; PARESTHESIA; POLYNEUROPATHY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DEMYELINATING DISEASES; FEMALE; HUMANS; MIDDLE AGED; NERVOUS SYSTEM; POLYNEUROPATHIES;

EID: 33646466150     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
2. Creange A, Lefaucheur JP, Authier FJ, Gherardi RK. [Cytokines and peripheral neuropathies]. Rev Neurol 1998;154:208-16.
3. Oka N, Akiguchi I, Kawasaki T, Mizutani K, Satoi H, Kimura J. Tumor necrosis factor-alpha in peripheral nerve lesions. Acta Neuropathol 1998;95:57-62.
4. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
5. Blumenauer B, Judd M, Wells G, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2002;3:CD003785.
6. Mikuls TR, Moreland LW Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Saf 2003;26:23-32.
7. ten Tusscher MP, Jacobs PJ, Busch MJ, de Graaf L, Diemont WL. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ 2003;326:579.
8. Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G, Thalidomide-induced neuropathy. Neurology 2002;59:1872-5.
9. Kaye O, Beckers CC, Paquet P, Arrese JE, Pierard GE, Malaise MG. The frequency of cutaneous vasculitis is not increased in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol 1996;23:253-7.
10. Puechal X, Said G, Hilliquin P, et al. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 1995;38:1618-29.
11. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65.
12. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-4.
13. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
14. Richez C, Blanco P, Lagueny A, Schaeverbeke T, Dehais J. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 2005;64:1468-70.
15. Robinson WH, Genovese MC, Moreland LW Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44:1977-83.